Press Release

Ophthalmic Surgical Devices Market Size Overview by Industry Trends, Growth and Analysis to 2026

Ophthalmic Surgical Devices Market by Top Key Players are Oertli Instrumente AG, Allergan, Hoya Corporation, Bausch & Lomb Incorporated, Johnson and Johnson Services, Inc., New World Medical, Inc., Glaukos, STAAR SURGICAL, ZEISS International, Alcon (Part of Novartis AG)

The global “ophthalmic surgical devices” market size is anticipated to reach USD 12.75 billion by 2026, registering a CAGR of 4.8% during the forecast period. Rising prevalence of cataract is one of the key factors fueling this market. The World Health Organization (WHO) defines cataract as “clouding of the lens of the eye which impedes the passage of light”. The WHO estimates that currently there are approximately 18 million around the world that are blind in both eyes due either to improper surgery or inaccessibility to advanced procedures. While this eye condition mostly occurs as a person ages, the WHO claims that other risk factors such as diabetes, exposure to UV light, and smoking are fast emerging as major grounds for cataract. Moreover, the International Agency for the Prevention of Blindness (IAPB) states that blindness from cataract is around 5% in developed countries and 50% in developing and underdeveloped nations. Increasing demand for ocular treatments from emerging economies is, therefore, expected to lead the ophthalmic surgical devices market trends in the upcoming decade.

Request a Sample Copy of the Research Report:

 Major Companies Profiled in the Ophthalmic Surgical Devices Market Report:

  • Oertli Instrumente AG
  • Allergan
  • Hoya Corporation
  • Bausch & Lomb Incorporated
  • Johnson and Johnson Services, Inc.
  • New World Medical, Inc.
  • Glaukos
  • ZEISS International
  • Alcon (Part of Novartis AG)

The above insights are provided in a recent Fortune Business Insights™ report, titled “Ophthalmic Surgical Devices Market Size, Share & Industry Analysis, By Product Type (Cataract Surgery Devices, Vitreoretinal Surgery Devices, Refractive Error Surgery Devices, Glaucoma Surgery Devices), By End-user (Hospitals, Ophthalmic Clinics, Others), and Regional Forecast, 2019-2026”. The report further states that the value of this market stood at USD 8.79 billion in 2018. The main highlights of the report include:

  • In-depth study of the competitive landscape with main focus on companies’ profiles, strategies, and products launched;
  • Meticulous segmentation of the market and research into individual segments;
  • Detailed analysis of the regional dynamics; and
  • Microscopic evaluation of the various drivers and restraints influencing the market.

Growing Number of Aged People Worldwide to Prove Beneficial for the Market

According to the WHO, aging is the primary reason for the development of eye diseases and conditions. The condition develops slowly as the strength of the lens in the eye deteriorates with age and diminishes vision. Therefore, as world population ages, the incidence of age-related ocular disorders is likely to rise. According to the Department of Economic and Social Affairs of the UN, by 2050, there will be close to 2.1 billion people crossing the age of 60. Estimates released by AGS Health in Aging Foundation reveal that 20% of the adults above 60 years of age developed cataract in one or both eyes in 2019. Further, Mayo Clinic reports that glaucoma, which occurs due to damaged optic nerve in people over the age of 60, is one of the top causes of blindness in the world. Thus, growing global geriatric population would boost the ophthalmic surgery devices market growth.

Industry Developments:

  • August 2019: New World Medical, a renowned company in ophthalmological devices, launched its brand new glaucoma drainage tool,  Ahmed ClearPath, in the US. The device consists of a flexible plate designed to align with the curvature of the eye and anteriorly placed suture fixation points for efficient drainage.
  • July 2019: The Irish pharmaceutical giant, Allergan, announced that its New Drug Application for the company’s Bimatoprost Sustained-Release has been accepted by the US FDA. If successful, the product would be the first-of-its-kind biodegradable implant for treating patients with glaucoma or ocular hypertension.

More Trending Topics from Fortune Business Insights:

Vaccines Market Global Opportunities, international Top Key Players, Regional Analysis, Growth Trends, Forecast to 2026

Contact Lenses Market Business Opportunity, Global Trend, Report Research, Future Growth, Key Findings and Forecast to 2026

Dale Martinez

Dale possesses an engineering degree in Electronics from the Georgia Institute of Technology. She is the sole contributor at the Healthcare IT column. Before opting to write, Dale worked at major firms such as Microsoft, Amazon, GE, Raytheon, and so on. She possesses vast knowledge about a variety of fields like IT, IoT, Telecommunications, Health Dialysis, photovoltaic, and many others. Dale is also a ballet dancer.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *